Notably, altered expression of VTCN1 [HR: 1.85, 95% confidence interval (CI): 1.12~3.05, Log-Rank Equal Curves p = 0.01451] and PDCD1LG2 (HR: 1.52, 95% CI: 1.02~2.26, Log-Rank Equal Curves p = 0.03619) in the TCGA HCC 361 patient cohort was associated with worse overall survival (Figures 3A,B). This evidence concerns the gene PDCD1LG2 and hepatocellular carcinoma.